A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Completed · Phase 3 · NCT04650854
Conditions: Generalized Myasthenia Gravis
At a glance
- Research payments reported, 2025
- $20,978
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 165
About the trial
- Sponsor
- UCB Biopharma SRL
- Tested
- Rozanolixizumab (drug)
- Dates
- Started 2021-02-03; completion 2024-01-25
- Results posted
- Yes
The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).
From ClinicalTrials.gov, last updated 2026-08-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB SA reported $20,978 in research payments for this study in 2025 (3 payments).
Products named: Rystiggo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gelasio A. Baras Pier, M.D Neurology · Miami, FL
- Chafic Karam, M.D. Neurology · Portland, OR
- Sheetal Shroff, MD Neurology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Houston Methodist Research Institute $9,226
- Y & L Advance Health Care Inc. $8,773
- Hospital of Univ of Pennsylvania, PA $2,979
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.